[Congressional Bills 107th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3246 Introduced in House (IH)]







107th CONGRESS
  1st Session
                                H. R. 3246

To amend title XVIII of the Social Security Act to provide for coverage 
  under the Medicare Program of oral drugs to reduce serum phosphate 
            levels in patients with end-stage renal disease.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            November 7, 2001

 Mr. Greenwood (for himself, Mr. Lewis of Georgia, Mr. Cardin, Mr. Tom 
Davis of Virginia, Mr. Buyer, Mr. Barton of Texas, Mr. Deal of Georgia, 
 Mr. Boucher, Mr. Whitfield, and Mr. Collins) introduced the following 
 bill; which was referred to the Committee on Energy and Commerce, and 
  in addition to the Committee on Ways and Means, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL


 
To amend title XVIII of the Social Security Act to provide for coverage 
  under the Medicare Program of oral drugs to reduce serum phosphate 
            levels in patients with end-stage renal disease.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. MEDICARE COVERAGE OF ORAL PHOSPHATE BINDING DRUGS FOR 
              INDIVIDUALS WITH END STAGE RENAL DISEASE.

    (a) Coverage.--Section 1861(s)(2) of the Social Security Act (42 
U.S.C. 1395x(s)(2)) is amended--
            (1) in subparagraph (U), by striking ``and'' at the end;
            (2) in subparagraph (V), by inserting ``and'' at the end; 
        and
            (3) by adding at the end the following new subparagraph:
            ``(W) an oral drug that--
                    ``(i) is approved by the Food and Drug 
                Administration;
                    ``(ii) may be dispensed only upon a prescription; 
                and
                    ``(iii) is prescribed for use in a regimen to treat 
                an individual with end stage renal disease for the 
                purpose of reducing serum phosphate levels;''.
    (b) Effective Date.--The amendments made by subsection (a) shall 
apply to drugs furnished on or after the date that is 90 days after the 
date of enactment of this Act.
                                 <all>